{"disease":{"id":"selected-advanced-solid-tumors","name":"selected advanced solid tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03530397","title":"A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":401,"lead_sponsor_name":"MedImmune LLC","has_results":false},{"nct_id":"NCT05631262","title":"SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":321,"lead_sponsor_name":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","has_results":false},{"nct_id":"NCT06877533","title":"A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"iTeos Belgium SA","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}